Wall Street analysts forecast that Edwards Lifesciences (EW) will report quarterly earnings of $0.62 per share in its upcoming release, pointing to a year-over-year decline of 11.4%. It is anticipated ...

Edwards Lifesciences EW is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform is positioned for continued ...

Edwards Lifesciences Corp. closed 14.52% below its 52-week high of $89.86, which the company achieved on July 16th.